 Genprex, Inc. NASDAQ:GNPX said the company has been issued a patent that covers using REQORSA Immunogene Therapy in conjunction with immune checkpoint inhibitors for lung cancer. Thomas Gallagher, senior vice president of Intellectual Property and Licensing at Genprex, said the United States Patent and Trademark Office has granted US Patent No. 